National Women’s Health Week: Can We “Have It All?”

05.15.13 | By

Can women really “have it all?” It is an age-old question that continues to generate significant societal interest and discussion.

Week in Review: Communicating for Positive Patient Outcomes

05.10.13 | By

Following our focus on young innovators this week, I’m reminded that ongoing research and innovation significantly improves the lives of patients and contributes to the health of our economy. The pace of innovation is staggering, and with so much information available at our fingertips, ensuring patients are utilizing reliable, accurate sources to make the best decisions for their health can be a challenge. Regular communication is essential.

I Am Research. Progress. Hope.

05.10.13 | By

Nobody better represents the exciting science of our sector than those who are rolling up their sleeves and engaging in innovative biopharmaceutical research every day. As a result, we at PhRMA and our member companies are excited to highlight the stories and lives of some of our inspiring scientists. These individuals epitomize the passion, diversity, excitement, commitment and intellectual prowess of biopharmaceutical scientists. And they set an example for future generations of promising biopharma researchers.

Hurricane Season is Coming!

05.10.13 | By

Hurricane season is coming. It starts in less than a month.  Now’s the time to get prepared.  Here’s a clip from the Barometer Bob Show on the Weather Radio Broadcast Network.  In this edition, Barometer Bob interviews RxResponse Executive Director Erin Mullen.

Medicines are a part of the solution

05.10.13 | By

IMS’ latest report, Declining Medicine Use and Costs: For Better or Worse, reasserts the value that medicines provide in improving patients’ health and saving money on future health care costs. It’s also a great example of how and why the life cycle of medicines works so well. 

Vendor Profile: The Antibody, The Scientist, and an Adorable Sheep; The Story of Abcam

05.10.13 | By

Last week I wrote about my experience at the US Chamber’s Small Business Summit, and noted that I would be profiling some smaller businesses who work with pharmaceutical manufacturing companies as vendors.

PhRMA Statement on FDA Benefit Risk Assessment Plan

WASHINGTON, D.C. (May 9, 2013) – Pharmaceutical Research and Manufacturers of America (PhRMA) Vice President of Scientific and Regulatory Affairs Sascha Haverfield, Ph.D., issued the following statement today on the Food and Drug Administration’s (FDA) Draft PDUFA V Implementation Plan: Structured Approach to Benefit-Risk Assessment in Drug Regulatory Decision Making:


PhRMA frequently hosts and participates in online and in-person events that delve into the science, policy and regulatory issues critical to biopharmaceutical innovation and patient access to medicines.

Biopharmaceutical Industry Pipeline panel discussion

Learn  about recent events:

Biopharmaceutical Scientists

05.08.13 | By

Edited 05.10.13

As an industry, we need to do a better job of telling our story – who we are, what we believe in, and why the work we are doing is so important.  If we don’t, we will continue to be misunderstood and the full value of innovative medicines may not be recognized. 

Merck Scientist Pioneered the Invention of More Than 40 Vaccines, Saving Millions of Lives

05.07.13 | By

In the (now famous) picture, a mumps-ridden Jeryl Hilleman screams at the camera while older sister Kristen cautiously holds the baby still enough to endure the prick of a needle held by their father, Merck vaccinologist Dr. Maurice Hilleman.  In the picture, Hilleman has the scowl of an anxious father heavy on his brow, and with good reason:  the cultures taken from baby Jeryl that March night in 1966 were later used by her father to develop the Measles, Mumps and Rubella (M.M.R.) vaccine, presently given to more than 95 percent of American children and saving millions of lives.


Subscribe to RSS - Opinion